{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:30:24Z","timestamp":1791639024555,"version":"4.3.4"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Record"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This clinical trial compared two formulations of desoxycortone pivalate (DOCP) for treating the mineralocorticoid deficit in dogs with primary hypoadrenocorticism (PH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>At veterinary clinics in the USA and France, dogs with PH (n=152) were randomised (3:1) to receive approximately monthly treatments with either the test product, Zycortal (Dechra), administered subcutaneously (n=113), or the control product, Percorten\u2010V (Novartis Animal Health), administered intramuscularly (n=39), both at an initial dose of 2.2\u2009mg\/kg DOCP. Treatment administrators were unblinded; veterinarians assessing clinical signs were blinded; owners were blinded until at least day 90, the primary end point. Veterinarians assessed treatment outcome based on all of the following: clinical signs; sodium concentrations; potassium concentrations. Dogs received concurrent glucocorticoid therapy throughout the trial. Non\u2010inferiority was assessed using a generalised linear mixed model to compare success rates between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Success rates at day 90 were similar between groups (per\u2010protocol population at day 90: Zycortal 87\/101, 86.2 per cent, Percorten\u2010V 29\/34, 85.1 per cent). Zycortal was non\u2010inferior to Percorten\u2010V as the upper limit of the 95 per cent CI for the difference between groups was 13.6 per cent. Polydipsia and polyuria were the most common clinical observations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both products, in combination with glucocorticoid therapy, were safe and effective in treating PH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/vr.105328","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T17:24:38Z","timestamp":1579800278000},"update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Randomised clinical non\u2010inferiority trial comparing two formulations of desoxycortone pivalate for the treatment of canine primary hypoadrenocorticism"],"prefix":"10.1002","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6486-8541","authenticated-orcid":false,"given":"Hayley","family":"Farr","sequence":"first","affiliation":[{"name":"Dechra Development LLC Overland Park Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beasley L","family":"Mason","sequence":"additional","affiliation":[{"name":"Dechra Development LLC Overland Park Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"Longhofer","sequence":"additional","affiliation":[{"name":"Dechra Development LLC Overland Park Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.1996.208.01.85"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.1996.tb02377.x"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4557-4456-5.00012-2"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1997.tb00072.x"},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2460\/javma.1993.202.03.392","article-title":"Efficacy of microcrystalline desoxycorticosterone pivalate for treatment of hypoadrenocorticism in dogs. DOCP Clinical Study Group","volume":"202","author":"Lynn RC","year":"1993","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_11_7_1","unstructured":"U.S. Food and Drug Administration.Freedom of information summary: Percorten V 1998. Available:https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/3622[Accessed Aug 2018]."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0007-1935(91)90091-Z"},{"key":"e_1_2_11_9_1","first-page":"647","article-title":"Clinical signs and laboratory abnormalities in 23 dogs with spontaneous hypoadrenocorticism","volume":"20","author":"Rakich PM","year":"1984","journal-title":"J Am Anim Hosp Assoc"},{"key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2460\/javma.1982.180.01.59","article-title":"Canine hypoadrenocorticism: report of 37 cases and review of 39 previously reported cases","volume":"180","author":"Willard MD","year":"1982","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/avj.12019"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.13815"},{"key":"e_1_2_11_13_1","first-page":"136","article-title":"Prednisone treatment alters the serum amylase and lipase activities in normal dogs without causing pancreatitis","volume":"48","author":"Fittschen C","year":"1984","journal-title":"Can J Comp Med"},{"key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2460\/ajvr.1993.54.11.1954","article-title":"Toxicity of desoxycorticosterone pivalate given at high dosages to clinically normal beagles for six months","volume":"54","author":"Chow E","year":"1993","journal-title":"Am J Vet Res"},{"key":"e_1_2_11_15_1","first-page":"729","volume-title":"Veterinary pharmacology and therapeutics","author":"Ferguson DC","year":"2018"},{"key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.2460\/javma.1993.202.11.1869","article-title":"Severe gastrointestinal tract hemorrhage in three dogs with hypoadrenocorticism","volume":"202","author":"Medinger TL","year":"1993","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_11_17_1","first-page":"1115","article-title":"[Studies on pharmacokinetics of 9 \u2010fluorohydrocortisone in the rat, guinea pig and dog] Untersuchungen zur Pharmakokinetik von 9\u03b1\u2010Fluorhydrocortison bei Ratte, Meerschweinchen und Hund","volume":"21","author":"Wenzl H","year":"1971","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.i4052"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.i2520"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2007.tb01933.x"}],"container-title":["Veterinary Record"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1136%2Fvr.105328","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1136\/vr.105328","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1136\/vr.105328","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bvajournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1136\/vr.105328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T08:22:04Z","timestamp":1761639724000},"score":1,"resource":{"primary":{"URL":"https:\/\/bvajournals.onlinelibrary.wiley.com\/doi\/10.1136\/vr.105328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/vr.105328"],"URL":"https:\/\/doi.org\/10.1136\/vr.105328","archive":["Portico"],"relation":{},"ISSN":["0042-4900","2042-7670"],"issn-type":[{"value":"0042-4900","type":"print"},{"value":"2042-7670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}